AstraZeneca Plans $1.5B Manufacturing Site for Global Production of ADC Cancer Drugs
Antibody drug conjugates have fast become a big piece of AstraZeneca’s revenue growth. The drugmaker is taking steps to ensure it has the production capacity to meet market demand for these cancer drugs, revealing plans for a $1.5 billion manufacturing …